23andMe Investor Day Presentation Deck
Our Scale Enables Real-Time
Genetics Health Research¹
1,876,573
High cholesterol
1,785,456
Depression
1,113,057
Asthma
634,734
Irritable Bowel
534,696
Arrhythmia
9,047
Systemic Sclerosis
358,275
Type 2 Diabetes
2,355,068
APOE e4 carriers
(Alzheimer's risk)
667,019
Eczema
107,126
UC / Crohn's
159,135
Coronary Artery
7,334
Sarcoidosis
37,853
Type 1 Diabetes
85,604
Epilepsy
250,764
Psoriasis
64,800
Barrett's Esophagus
42,836
Pulmonary Embolism
4,528
Idiopathic Pulmonary
Fibrosis
¹ As of August 2, 2021. 2 As of September 2021. 3 23andMe COVID-19 manuscript live on MedRXiv September 7, 2020.
1,287,060
COVID-19 study participants
COVID-19 Research
March 16
April 6
June 8
750K
Consumers participated
in the COVID-19 study
in the first 90 days
Sept. 7
(2020)
Kicked Off Study
Launched Study
Preliminary Findings
Posted Findings³
Re-contactable Customers
Participate in Health ResearchView entire presentation